Document is current
Any future updates will be listed below
-
Authors
Miranda, Joao https://orcid.org/0000-0003-1273-3108
Dave, Priya https://orcid.org/0000-0002-6367-2854
Kemel, Yelena https://orcid.org/0000-0002-5042-5651
Sheikh, Rania
Zong, Grace
Calderon, Lina Posada
Will, Marie
Liu, Ying L.
Walsh, Michael https://orcid.org/0000-0001-5006-6778
Stadler, Zsofia K. https://orcid.org/0000-0002-6985-2864
Offit, Kenneth
Latham, Alicia
Mandelker, Diana
Chen, Ying-Bei
Andrieu, Pamela Causa
Carlo, Maria Isabel https://orcid.org/0000-0002-4786-7408
- License Information
-
More Information
Article History
Received: 23 November 2023
Revised: 13 April 2024
Accepted: 25 April 2024
First Online: 1 June 2024
Competing interests
: YLL reports research funding from AstraZeneca, GSK and Repare Therapeutics unrelated to this work. ZKS’s immediate family member serves as a consultant in Ophthalmology for Adverum, Genentech, Neurogene, Novartis, Optos Plc, Outlook Therapeutics, and Regeneron outside the submitted work. Dr. Stadler serves as an Associate Editor for JCO Precision Oncology and as a Section Editor for UpToDate. MIC reports honoraria from OncLive. All other authors declare no conflict of interest.
: This study was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB).
